Calcium channel blockers and clinical outcomes in patients with continuous-flow left ventricular assist devices

被引:0
|
作者
Tie, Hongtao [1 ,2 ]
Li, Zhenhan [3 ,4 ]
Welp, Henryk [1 ]
Guha, Avirup [5 ,6 ]
Caraballo, Cesar [7 ,8 ]
Deschka, Heinz [1 ]
Shi, Rui [9 ]
Zheng, Xiaoqing [10 ]
Martens, Sven [1 ]
Sindermann, Jurgen [1 ]
Chen, Dan [2 ]
Wu, Qingchen [2 ]
Martens, Sabrina [1 ]
机构
[1] Univ Hosp Muenster, Dept Cardiothorac Surg, Albert Schweitzer Campus 1, D-48149 Munster, Germany
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Chongqing, Peoples R China
[3] Chongqing Tradit Chinese Med Hosp, Dept Endocrinol, Chongqing, Peoples R China
[4] Univ Hosp Muenster, Dept Anaesthesiol Intens Care Med & Pain Med, Munster, Germany
[5] Augusta Univ, Med Coll Georgia, Dept Internal Med, Div Cardiol, Augusta, GA USA
[6] Ohio State Univ, Med Ctr, Cardiooncol Program, Div Cardiol, Columbus, OH USA
[7] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA
[8] Ctr Outcomes Res & Evaluat, New Haven, CT USA
[9] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Crit Care Med, Guangzhou, Peoples R China
[10] Univ Pittsburgh, Pittsburgh, PA USA
来源
ESC HEART FAILURE | 2024年 / 11卷 / 01期
关键词
Calcium channel blocker; LVAD; Survival; Adverse events; WORSENING RENAL-FUNCTION; CHRONIC HEART-FAILURE; EJECTION FRACTION; TRANSPLANTATION; ASSOCIATION; AMLODIPINE; SOCIETY; RISK;
D O I
10.1002/ehf2.14576
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsCurrent guidelines suggest calcium channel blockers (CCBs) as the second or third option for blood pressure management in patients with left ventricular assist device (LVAD). However, the clinical outcomes of patients with LVAD who receive CCBs remain unclear. Our study aims to analyse the association of CCBs with clinical outcomes in patients after LVAD implantation.Methods and resultsThis is a retrospective analysis based on the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) from 2006 to 2017, and adult patients who were alive with LVAD and CCB treatment information at 6 months after implantation were included. Among 10 717 patients, 1369 received CCBs 6 months after implantation, and there was an increasing trend of CCB use after LVAD. Patients receiving CCB therapy at 6 months had a similar 5 year survival rate to those not receiving CCB [49.6%, 95% confidence interval (CI): 47.5-51.7% vs. 51.1%, 95% CI: 45.3-56.7%]. In both Cox and competing risk regressions after adjusting for confounding factors, CCB treatment at 6 months after implantation was not associated with long-term mortality [hazard ratio (HR): 1.03, 95% CI: 0.91-1.17, P = 0.624 and subdistribution HR (SHR): 1.07, 95% CI: 0.95-1.22, P = 0.260]. Consistently, in time-varying models, CCB treatment was not linked to long-term mortality (HR: 0.97, 95% CI: 0.87-1.09, P = 0.682 and SHR: 1.05, 95% CI: 0.94-1.18, P = 0.359). This null association remained in subgroup analysis according to device strategy and propensity-matching analyses. Neurological dysfunction, stroke, bleeding, rehospitalization, and renal dysfunction were more likely to occur among those with CCB when compared with those without CCB treatment.ConclusionsIn patients with LVAD, CCB therapy fails to show benefits in long-term survival and is associated with increased incidences of neurological dysfunction, bleeding, renal dysfunction, and rehospitalization.
引用
收藏
页码:271 / 281
页数:11
相关论文
共 50 条
  • [1] Metabolic Dysfunction in Continuous-Flow Left Ventricular Assist Devices Patients and Outcomes
    Nguyen, Ann B.
    Imamura, Teruhiko
    Besser, Stephanie
    Rodgers, Daniel
    Chung, Ben
    Raikhelkar, Jayant
    Kalantari, Sara
    Smith, Bryan
    Sarswat, Nitasha
    LaBuhn, Colleen
    Jeevanandam, Valluvan
    Kim, Gene
    Sayer, Gabriel
    Uriel, Nir
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (22):
  • [2] Effect of obesity on outcomes in patients undergoing implantation of continuous-flow left ventricular assist devices
    Volkovicher, Nastasya
    Kurihara, Chitaru
    Critsinelis, Andre
    Kawabori, Masashi
    Sugiura, Tadahisa
    Manon, Marcos, II
    Civitello, Andrew B.
    Morgan, Jeffrey A.
    JOURNAL OF ARTIFICIAL ORGANS, 2018, 21 (02) : 180 - 187
  • [3] Impact of Cardiac Resynchronization Therapy on Clinical Outcomes in Patients With Continuous-Flow Left Ventricular Assist Devices
    Gopinathannair, Rakesh
    Birks, Emma J.
    Trivedi, Jaimin R.
    Mccants, Kelly C.
    Sutton, Brad S.
    Deam, Allen G.
    Slaughter, Mark S.
    Hottigoudar, Raseimi U.
    JOURNAL OF CARDIAC FAILURE, 2015, 21 (03) : 226 - 232
  • [4] Contemporary outcomes of continuous-flow left ventricular assist devices-a systematic review
    McNamara, Nicholas
    Narroway, Harry
    Williams, Michael
    Brookes, John
    Farag, James
    Cistulli, David
    Bannon, Paul
    Marasco, Silvana
    Potapov, Evgenij
    Loforte, Antonio
    ANNALS OF CARDIOTHORACIC SURGERY, 2021, 10 (02) : 186 - 208
  • [5] Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices
    Martucci, Gennaro
    Pappalardo, Federico
    Subramanian, Harikesh
    Ingoglia, Giulia
    Conoscenti, Elena
    Arcadipane, Antonio
    NUTRIENTS, 2021, 13 (03) : 1 - 17
  • [6] Clinical management of continuous-flow left ventricular assist devices in advanced heart failure
    Slaughter, Mark S.
    Pagani, Francis D.
    Rogers, Joseph G.
    Miller, Leslie W.
    Sun, Benjamin
    Russell, Stuart D.
    Starling, Randall C.
    Chen, Leway
    Boyle, Andrew J.
    Chillcott, Suzanne
    Adamson, Robert M.
    Blood, Margaret S.
    Camacho, Margarita T.
    Idrissi, Katherine A.
    Petty, Michael
    Sobieski, Michael
    Wright, Susan
    Myers, Timothy J.
    Farrar, David J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (04) : S1 - S39
  • [7] Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices
    Galand, Vincent
    Flecher, Erwan
    Auffret, Vincent
    Boule, Stephane
    Vincentelli, Andre
    Dambrin, Camille
    Mondoly, Pierre
    Sacher, Frederic
    Nubret, Karine
    Kindo, Michel
    Cardi, Thomas
    Gaudard, Philippe
    Rouviere, Philippe
    Michel, Magali
    Gourraud, Jean-Baptiste
    Defaye, Pascal
    Chavanon, Olivier
    Verdonk, Constance
    Ghodbane, Walid
    Pelce, Edeline
    Gariboldi, Vlad
    Pozzi, Matteo
    Obadia, Jean-Francois
    Litzler, Pierre-Yves
    Anselme, Frederic
    Babatasi, Gerard
    Belin, Annette
    Garnier, Fabien
    Bielefeld, Marie
    Hamon, David
    Radu, Costin
    Pierre, Bertrand
    Bourguignon, Thierry
    Eschalier, Romain
    D'Ostrevy, Nicolas
    Bories, Marie-Cecile
    Marijon, Eloi
    Vanhuyse, Fabrice
    Blangy, Hugues
    Verhoye, Jean-Philippe
    Leclercq, Christophe
    Martins, Raphael P.
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2018, 4 (09) : 1166 - 1175
  • [8] Clinical Implications of Physiologic Flow Adjustment in Continuous-Flow Left Ventricular Assist Devices
    Tchantchaleishvili, Vakhtang
    Luc, Jesica G. Y.
    Cohan, Caitlin M.
    Phan, Kevin
    Hubbert, Laila
    Day, Steven W.
    Masey, H. Todd
    ASAIO JOURNAL, 2017, 63 (03) : 241 - 250
  • [9] Cerebrovascular Events After Continuous-Flow Left Ventricular Assist Devices
    Tahsili-Fahadan, Pouya
    Curfman, David R.
    Davis, Albert A.
    Yahyavi-Firouz-Abadi, Noushin
    Rivera-Lara, Lucia
    Nassif, Michael E.
    LaRue, Shane J.
    Ewald, Gregory A.
    Zazulia, Allyson R.
    NEUROCRITICAL CARE, 2018, 29 (02) : 225 - 232
  • [10] Neurologic Events in Continuous-Flow Left Ventricular Assist Devices
    Kadakkal, Ajay
    Najjar, Samer S.
    CARDIOLOGY CLINICS, 2018, 36 (04) : 531 - +